## HELLENIC SOCIETY FOR THE STUDY OF INBORN ERRORS OF METABOLISM, Greece

1. Respond	ent Profile
1.1 Please indicate the type of organisation on behalf of which you are responding to this consultation:	Health professionals' organisations (e.g. doctors, nurses, managers)
Please indicate level:	National level organisation
Please indicate for what the administration is responsible:	
1.1.1. Other (please specify):	SCIENTIFIC SOCIETY
1.2 Please indicate the name of your organisation or centre:	HELLENIC SOCIETY FOR THE STUDY OF INBORN ERRORS OF METABOLISM (HSSIEM)
1.3 Please indicate the country where your organsation/centre is located/has its headquarters or main representative office in Europe:	EL:
1.4 Please indicate the number of EU Member States and EEA countries (Norway, Iceland, Lichtenstein) and accessing country (Croatia) in which your organisation conducts business/is represented:	2
1.5 If need be, can we contact you by e-mail to obtain further information on your submission?	Yes
1.5.1 Please provide an e-mail address where we can contact you:	hellenicssiem@gmail.com
1.6 Please provide us with a contact person (incl jobtitle and daytime phone number):	e Dr. MARINA MORAITOU SECRETARY HSSIEM tel. 00302107467788
1.7 Please provide additional contact details if needed:	

2. Involvement of your organisation in the matter of contents in highly special	
2.1 How would you describe your organisation's knowledge of CoE and HSHC?	d Very high
2.1.1 Space for further comments:	
2.2. What aspects or domains related to the topic of CoE and HSHC would correspond to your organisation's key knowledge? (cross any that applies)	Highly specialised healthcare provision Priorities, description and characteristics of CoE and HSHC Management and organisational aspects of highly specialized healthcare Professional performance, clinical practice, quality and safety of specialized healthcare
2.2.1. Space for further comments:	
2.3 Is highly specialised healthcare a priority in your organisation's strategies and work plans?	Very high
2.3.1 Space for further comments:	
2.4. What specific field of healthcare services/specialities are most relevant for your centre/organisation's field of work?	Medical speciality
Please specify:	Biochemical genetics, neurology, paediatrics
2.5. Has your organisation/centre been directly involved in the design or assessment of professional standards and criteria related with highly specialised healthcare?	Occasionally
2.5.1 Please describe your role in such actions/projects:	

2.6. Has your organisation been involved in projects/activities supported by the Commission in relation with HSHC or professional and technical criteria/standards in highly specialised healthcare?	No
2.7. Do you have concrete examples based on your own organisation's	Yes
experience or could you provide us with references or links to	
documents related with professional criteria and standards in highly	
specialised healthcare/CoE or HSHC (e.g. quality criteria, guidelines,	
consensus documents)?	
2.7.1 Space for further comments:	
2.13. What is the scope of the network?	
2.14. Which kind of network?	
2.14.1 Space for further comments:	
2.15. Would you be interested in applying to the process to be	
considered Centre of Excellence of the future European Reference	
Network? (1 = not interested at all, 5 = very interested)	
2.15.1 Space for further comments:	

## 3. Proposed criteria for ERN (scope, general and specific criteria)

3.1 Criteria related with diseases or condition	ons in order to be considered under the scope of the ERN
3.1.1. Need of highly specialised healthcare	5
3.1.1.1. Complexity of the diagnosis and treatment	5
3.1.1.2. High cost of treatment and resources	5

3.1.1.3. Need of advanced/highly specialised medical equipment or infrastructures	5
3.1.2. Need of particular concentration of expertise and resources	5
3.1.2.1. Rare expertise/need of concentration of cases	5
3.1.2.2. Low prevalence/incidence/number of cases	5
3.1.2.3. Evaluated experiences of Member States	5
3.1.3. Based on high-quality, accessible and cost-effective healthcare	5
3.1.3.1. Evidence of the safety and favourable risk-benefit analysis	5
3.1.3.2. Feasibility and evidence of the value and potential positive outcome (clinical)	4
3.1.4. Do you recommend any additional criteria or option that would effectively address the issue?	No
3.1.5. Would you prioritise or suggest any concrete disesase or group of diseases to be addressed by the future ERN according to the above criteria?	Yes
3.1.5.1 Explain your proposal in free text:	Inherited Metabolic Disorders(IEM): Lysosomal Storage Diseases, Peroxisomal Leukodystrophies, Congenital Disorders of Glycosylation etc, fulfill the ERN scope and require clinical-lab networking

## 3.2. General criteria of the centres wishing to join a European Reference Network

3.2.1. Organisation and management

3.2.2. Patients empowerment and centered care	4
3.2.3. Patient care, clinical tools and health technology assessment	5
3.2.4. Quality, patient safety and evaluation framework policies	5
3.2.5. Business continuity, contingency planning and response capacity	5
3.2.6. Information systems, technology and e-health tools and applications	5
3.2.7. Overall framework and capacity for research and training	4
3.2.8. Specific commitment of the management/direction of the centre/hospital to ensure a full and active participation in the ERN	5
3.2.9. Do you recommend any additional option that would effectively address the issue?	No
3.2.9.1. Space for further comments:	

3.3. Specific criteria reg	garding the areas of expertise
3.3.1. Competence, experience and good outcomes and care	5
3.3.2. Specific resources and organisation:	5
3.3.2.1. Human resources	5
3.3.2.2. Team/centre organisation	5
3.3.2.3. Structural conditions	5

5
5
5
4
4
5
l No
ERN governance, interaction of members ,financial support if any should be clearly defined. Adjustments depending on the scope of ERN possible, eg laboratory networks for IEM